Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZYVPB)

Drug Name
ABX-MA1 Drug Info
Synonyms Anti-MUC18 MAb, Abgenix
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMZYVPB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cell adhesion molecule (CADM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PRX003 DM5KI6X Psoriasis vulgaris EA90 Phase 1 [3]
ABS-205 DMALPDW Neurodegenerative disorder 8A20-8A23 Terminated [4]
CY-1748 DM0X147 Deep vein thrombosis BD71 Terminated [5]
ICM-3 DMDBICR Graft-versus-host disease 4B24 Terminated [6]
GM-7050 DMEVIP9 Inflammation 1A00-CA43.1 Terminated [7]
Rovelizumab DM4VCJI Cerebrovascular disease 8B2Z Terminated [8]
NPC-17923 DMD01GK Rheumatoid arthritis FA20 Terminated [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cell adhesion molecule (CADM) TTD26RC NOUNIPROTAC Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016814)
2 Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21).
5 US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation.
6 Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60.
7 US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
8 Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
9 Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72.